Historical standards for H3K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Approval Alert | Dordaviprone in H3 K27M-Mutated Diffuse Midline Glioma
Historical standards for H3 K27M–mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Supporting data for the accelerated approval of dordaviprone come from 5 open-label trials in H3 K27M-mutant diffuse midline glioma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
3
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
4
Tarlatamab Requires Strategic Toxicity Monitoring and Management in ES-SCLC
5
